Laser balloon ablation for AF: A systematic review and meta-analysis

Area of Science:

• Cardiology
• Medical Devices
• Electrophysiology

Background:

• The HeartLight laser balloon ablation system received FDA approval in 2016 for treating paroxysmal atrial fibrillation (AF).
• Numerous studies have reported outcomes, but a systematic synthesis of data is needed.

Purpose of the Study:

• To systematically review and synthesize published outcome data for AF ablation using the laser balloon system.
• To evaluate the efficacy and safety of laser balloon ablation for atrial fibrillation.

Main Methods:

• Systematic review and meta-analysis of published human studies with at least 6-month follow-up.
• Included outcomes: acute procedural results, 12-month efficacy, safety, and procedure duration.
• Analyzed aggregated data using random effects models with a Bayesian hierarchical approach.

Main Results:

• 17 studies with 1188 patients (80% paroxysmal AF) were included.
• 98.8% pulmonary vein isolation achieved acutely.
• Pooled 12-month freedom from atrial arrhythmia was 74.3% for paroxysmal AF and 72.9% for all AF types.
• Phrenic nerve injury was the most common complication (2.6%), typically resolving.

Conclusions:

• Laser balloon ablation demonstrates high effectiveness in pulmonary vein isolation.
• Safety and 12-month efficacy appear favorable compared to other AF ablation technologies.
• This supports laser balloon ablation as a viable option for AF treatment.